Chronic Obstructive Pulmonary Disease Drugs Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

MARKET INTRODUCTION

Chronic obstructive pulmonary disease is a type of obstructive lung disease characterized by long-term breathing problems and low airflow. The primary symptoms include shortness of breath and cough with sputum production. Chronic obstructive pulmonary disease is a progressive disease, meaning it typically aggravates over time. The two different kinds of COPD are emphysema and chronic bronchitis. Chronic bronchitis is a productive cough present for at least three months each year for two years. The individuals with such a cough are at a greater risk of developing COPD. Emphysem is also used for the abnormal air or other gas within tissues. The most common cause is tobacco smoking, with a smaller number of cases due to air pollution and genetics. In the developing world, familiar sources of air pollution are wood combustion, and cooking fires. Moreover, long-term exposure to these risk factors causes an inflammatory reaction in the lungs, leading to narrowing of the small air passages and breakdown of lung tissue. COPD is diagnosed based on low airflow as measured by lung function tests.

MARKET DYNAMICS

The chronic obstructive pulmonary disease drug market has shown a significant evolution over the forecast period. The key driving factors include increased incidence and prevalence of COPD, technological advancements, and a growing aging population. As per the US Census Bureau's Statistics, as of 2021, the total number of people aged between 65 and older exceeded 50 million. According to the United Nations, during 2015-2031, the number of older persons aged 60 years or worldwide is projected to grow from 901 million to more than 1.4 billion. The significant factors that cause COPD are exposure to air pollution , cigarette smoke, rare genetic condition, chemical fumes or dust, among others. The Lancet Respiratory Medicine published an article in 2021, revealed that permanent lung tissue damage caused due to COPD begins even before the patient experiences any symptoms. Besides, technological advancements are anticipated to provide lucrative market opportunities. However, limitations of traditional treatments, such as late-onset of action and low efficacy, and stringent government regulations are likely to restrict the market growth.

MARKET SCOPE

The "Chronic Obstructive Pulmonary Disease Drugs Market Analysis to 2031" is a specialized and in-depth study of pharmaceuticals in the healthcare industry, focusing on the global market trend analysis. This report outlines the chronic obstructive pulmonary disease drugs market with detailed market segmentation by disease type, therapy, and end-user. The chronic obstructive pulmonary disease drug market is expected to witness high growth during the forecast period. The report focuses on the vital statistics on the market status of the leading players in the chronic obstructive pulmonary disease drugs market and offers key trends and opportunities.

MARKET SEGMENTATION

The market is segmented based on disease type, therapy, and end-user. Based on disease type, the market is categorized as emphysema and chronic bronchitis. Based on the therapy, the market is segmented as bronchodilators, steroids, anti-inflammatory drugs, and others. Based on the end-user, the market is segmented as hospitals, clinics, and others.

REGIONAL FRAMEWORK

The report lays out a detail outline of the industry, including both qualitative and quantitative information. The report gives a sketch and forecast of the chronic obstructive pulmonary disease drugs market based on various segments. It also consists of market size and forecast estimates from the year 2021 to2031 concerning five major regions: North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South & Central America. The market by each region is then subsegmented into respective countries and segments. The report consists of the analysis and forecast of eighteen countries globally and the recent trend and opportunities prevailing in the region.

The report analyzes factors affecting the chronic obstructive pulmonary disease drug market from both the demand and supply side. Furthermore, it evaluates market dynamics affecting the market during the forecast period, i.e., drivers, restraints, opportunities, and future trends. The report also comprises of precise PEST analysis for all five regions, namely; North America, Europe, APAC, MEA, and South & Central America, after evaluating political, economic, social, and technological factors affecting the chronic obstructive pulmonary disease drugs market in these regions.

MARKET PLAYERS

The report contains critical developments in the chronic obstructive pulmonary disease drugs market as organic and inorganic growth strategies. Various enterprises focus on organic growth strategies like product launches, product approvals, and others, such as patents and events. Inorganic growth strategies observed in the market were acquisitions and partnerships & collaborations. These activities have paved the way for the expansion of business and customer base of market players. The market players from the chronic obstructive pulmonary disease drugs market are anticipated to have profitable growth opportunities in the coming years with the rising demand for the chronic obstructive pulmonary disease drugs market globally. Given below is the list of few companies engaged in the chronic obstructive pulmonary disease drug market.

The report also consists of the profiles of key players in the chronic obstructive pulmonary disease drugs market, along with their SWOT analysis and market strategies. Additionally, the report elaborates on leading industry players with information on company profiles, components, and services provided, financial information of the last three years, critical development in the past five years.

•  AstraZeneca
  
•  Boehringer Ingelheim International GmbH
  
•  Mylan N.V.
  
•  Teva Pharmaceutical Industries Ltd
  
•  GlaxoSmithKline plc
  
•  Abbott
  
•  Astellas Pharma
  
•  Circassia Pharmaceuticals plc
  
•  Pfizer Inc.
  
•  F. Hoffmann-La Roche Ltd
  

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and provides various customization options in the current study.

Chronic Obstructive Pulmonary Disease Drugs Report Scope